Bloom_1987_J.Pharmacol.Exp.Ther_240_51

Reference

Title : Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung - Bloom_1987_J.Pharmacol.Exp.Ther_240_51
Author(s) : Bloom JW , Halonen M , Lawrence LJ , Rould E , Seaver NA , Yamamura HI
Ref : Journal of Pharmacology & Experimental Therapeutics , 240 :51 , 1987
Abstract :

We have characterized the binding of the selective muscarinic antagonist [3H]pirenzepine ([3H])PZ) and the classical muscarinic antagonist (-)-[3H]quinuclidinyl benzilate ((-)-[3H]QNB) to muscarinic cholinergic sites in rabbit peripheral lung membranes. For both radioligands, high affinity binding with pharmacologic specificity was demonstrated. The high affinity Kd for [3H]PZ binding determined from saturation isotherms was 4.5 nM and the Kd for (-)-[3H]QNB binding was 6.2 pM. Comparison of the total binding capacity values determined by saturation experiments with [3H] PZ and (-)-[3H]QNB demonstrates that approximately 78% of the total muscarinic binding sites in rabbit peripheral lung bind [3H]PZ with high affinity. There was no significant effect of the guanine nucleotide, guanyl-5'-yl imidodiphosphate, on the inhibition of (-)-[3H]QNB binding by the muscarinic agonist carbachol in peripheral lung membranes. If the pulmonary muscarinic receptor with high affinity for PZ proves to have an important role in bronchoconstriction, its characterization could result in the development of more selective bronchodilators.

PubMedSearch : Bloom_1987_J.Pharmacol.Exp.Ther_240_51
PubMedID: 3806397

Related information

Citations formats

Bloom JW, Halonen M, Lawrence LJ, Rould E, Seaver NA, Yamamura HI (1987)
Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung
Journal of Pharmacology & Experimental Therapeutics 240 :51

Bloom JW, Halonen M, Lawrence LJ, Rould E, Seaver NA, Yamamura HI (1987)
Journal of Pharmacology & Experimental Therapeutics 240 :51